Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $46.43.

A number of analysts have weighed in on the stock. BTIG Research raised shares of Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $50.00 target price on the stock in a research note on Wednesday, March 27th. HC Wainwright upped their target price on Outlook Therapeutics to $30.00 and gave the stock a “buy” rating in a report on Monday, March 25th. Chardan Capital upgraded Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Thursday, February 15th. Guggenheim upgraded Outlook Therapeutics from a “neutral” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Thursday, January 25th. Finally, Brookline Capital Management upgraded shares of Outlook Therapeutics from a “hold” rating to a “buy” rating and set a $31.40 price objective for the company in a report on Thursday, January 25th.

Outlook Therapeutics Stock Down 3.4 %

Outlook Therapeutics stock opened at $8.21 on Wednesday. The stock has a market cap of $106.81 million, a PE ratio of -2.05 and a beta of 0.28. Outlook Therapeutics has a 12-month low of $4.00 and a 12-month high of $40.60. The business’s 50-day moving average price is $8.53 and its two-hundred day moving average price is $8.59.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings results on Wednesday, February 14th. The company reported ($0.80) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.20. As a group, analysts expect that Outlook Therapeutics will post -2.99 earnings per share for the current year.

Institutional Trading of Outlook Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Gables Capital Management Inc. lifted its position in shares of Outlook Therapeutics by 132.3% in the 3rd quarter. Gables Capital Management Inc. now owns 154,500 shares of the company’s stock worth $34,000 after purchasing an additional 88,000 shares during the period. Scotia Capital Inc. raised its stake in Outlook Therapeutics by 420.9% during the third quarter. Scotia Capital Inc. now owns 338,439 shares of the company’s stock worth $75,000 after buying an additional 273,463 shares during the last quarter. Finally, Rosalind Advisors Inc. acquired a new position in Outlook Therapeutics in the first quarter valued at $3,723,000. 11.20% of the stock is currently owned by institutional investors.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.